JP2012531612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531612A5 JP2012531612A5 JP2012518798A JP2012518798A JP2012531612A5 JP 2012531612 A5 JP2012531612 A5 JP 2012531612A5 JP 2012518798 A JP2012518798 A JP 2012518798A JP 2012518798 A JP2012518798 A JP 2012518798A JP 2012531612 A5 JP2012531612 A5 JP 2012531612A5
- Authority
- JP
- Japan
- Prior art keywords
- macro
- cancer
- expression
- patient
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000898914 Tetrahymena thermophila (strain SB210) Histone H2A.1 Proteins 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 238000003745 diagnosis Methods 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 102100034528 Core histone macro-H2A.1 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 108010034959 macroH2A histone Proteins 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 210000002381 plasma Anatomy 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000001261 affinity purification Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000011532 immunohistochemical staining Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09008679A EP2270510A1 (en) | 2009-07-02 | 2009-07-02 | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| EP09008679.4 | 2009-07-02 | ||
| PCT/EP2010/004008 WO2011000573A1 (en) | 2009-07-02 | 2010-07-02 | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531612A JP2012531612A (ja) | 2012-12-10 |
| JP2012531612A5 true JP2012531612A5 (enExample) | 2013-08-08 |
| JP5792165B2 JP5792165B2 (ja) | 2015-10-07 |
Family
ID=41100520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012518798A Expired - Fee Related JP5792165B2 (ja) | 2009-07-02 | 2010-07-02 | ヒストンマクロｈ２ａアイソフォームに基づいて癌再発のリスクを予測する診断のための判断材料を提供する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120171225A1 (enExample) |
| EP (2) | EP2270510A1 (enExample) |
| JP (1) | JP5792165B2 (enExample) |
| CN (1) | CN102472753B (enExample) |
| AU (1) | AU2010268389B2 (enExample) |
| BR (1) | BRPI1011925A2 (enExample) |
| CA (1) | CA2766656A1 (enExample) |
| ES (1) | ES2681687T3 (enExample) |
| SG (1) | SG177398A1 (enExample) |
| WO (1) | WO2011000573A1 (enExample) |
| ZA (1) | ZA201109381B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
| EP3508855A1 (en) * | 2018-01-05 | 2019-07-10 | Allianz Pharmascience Ltd | Method for the selection of patients and kit |
| EP3546944A1 (en) * | 2018-03-30 | 2019-10-02 | Universite d'Aix-Marseille (AMU) | Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN111896740B (zh) * | 2019-05-06 | 2025-02-11 | 山东大学 | 诊断或预测生育缺陷的试剂盒 |
| CN119736252B (zh) * | 2025-01-15 | 2025-06-27 | 首都医科大学 | 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2197915B (en) | 1986-11-19 | 1990-11-14 | Rolls Royce Plc | Improvements in or relating to fluid bearings |
| EP1388734B1 (en) * | 2002-08-01 | 2004-03-03 | MTM Laboratories AG | Method for solution based diagnosis |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20030190640A1 (en) * | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20050085628A1 (en) * | 2002-01-31 | 2005-04-21 | Kinya Yoda | Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same |
| CN100480382C (zh) * | 2002-08-16 | 2009-04-22 | 抗癌公司 | 实时测量细胞反应 |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| WO2004106511A1 (ja) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物 |
| EP1682904A2 (en) * | 2003-11-04 | 2006-07-26 | Roche Diagnostics GmbH | Method for distinguishing who classified aml subtypes |
| DE102004037860A1 (de) * | 2004-08-04 | 2006-03-16 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen |
| WO2006119435A2 (en) * | 2005-05-04 | 2006-11-09 | Invitrogen Corporation | Identification of cancer biomarkers and phosphorylated proteins |
| CA2612021A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US9150628B2 (en) * | 2005-11-14 | 2015-10-06 | Centre National De La Recherche Scientifique (Cnrs) | PARP inhibitors |
| WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| JP2008292424A (ja) * | 2007-05-28 | 2008-12-04 | Nippon Medical School | 腫瘍の検出方法 |
| BRPI0815460A2 (pt) * | 2007-09-07 | 2019-02-26 | Univ Bruxelles | kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos |
| CA2726531A1 (en) * | 2008-06-05 | 2009-12-10 | University Health Network | Compositions and methods for classifying lung cancer and prognosing lung cancer survival |
-
2009
- 2009-07-02 EP EP09008679A patent/EP2270510A1/en not_active Withdrawn
-
2010
- 2010-07-02 SG SG2011096849A patent/SG177398A1/en unknown
- 2010-07-02 AU AU2010268389A patent/AU2010268389B2/en not_active Ceased
- 2010-07-02 EP EP10730098.0A patent/EP2449383B1/en not_active Not-in-force
- 2010-07-02 CN CN201080029880.5A patent/CN102472753B/zh not_active Expired - Fee Related
- 2010-07-02 US US13/380,324 patent/US20120171225A1/en not_active Abandoned
- 2010-07-02 WO PCT/EP2010/004008 patent/WO2011000573A1/en not_active Ceased
- 2010-07-02 BR BRPI1011925A patent/BRPI1011925A2/pt not_active Application Discontinuation
- 2010-07-02 CA CA2766656A patent/CA2766656A1/en not_active Abandoned
- 2010-07-02 JP JP2012518798A patent/JP5792165B2/ja not_active Expired - Fee Related
- 2010-07-02 ES ES10730098.0T patent/ES2681687T3/es active Active
-
2011
- 2011-12-20 ZA ZA2011/09381A patent/ZA201109381B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220334128A1 (en) | Method for the enrichment of circulating tumor dna | |
| Cheng et al. | Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma | |
| JP2012531612A5 (enExample) | ||
| Ghazani et al. | Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance | |
| Wang et al. | Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma | |
| Santos et al. | Liquid biopsy: The value of different bodily fluids | |
| JP2017520763A5 (enExample) | ||
| Black et al. | The search for biomarkers of hepatocellular carcinoma and the impact on patient outcome | |
| Liu et al. | Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients | |
| CN102472753B (zh) | 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法 | |
| JP2019510974A (ja) | 癌検出のためのヌクレオソーム−転写因子複合体の使用 | |
| Seo et al. | Epidemiologic study of human epidermal growth factor receptor 2 expression in advanced/metastatic gastric cancer: an assessment of human epidermal growth factor receptor 2 status in tumor tissue samples of gastric and gastro-esophageal junction cancer | |
| Meng et al. | Expression of human epidermal growth factor receptor-2 in resected rectal cancer | |
| Idriss et al. | Analysis of lamin B1, vimentin and anti-Ku86 as prospective biomarkers of hepatocellular carcinoma in patients with hepatitis C virus infection | |
| JP2021019612A (ja) | 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 | |
| CN103562722A (zh) | 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途 | |
| Wang et al. | Use of cytokeratin-19 concentration to assess early recurrence and prognosis of hepatitis B virus-related hepatocellular carcinoma following radical resection in patients with a low serum alpha-fetoprotein concentration | |
| Li et al. | Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer | |
| JP2017529074A5 (enExample) | ||
| JP2010216826A (ja) | 新規腫瘍マーカーを用いた乳癌の検査方法 | |
| Rutkowska-Kawalec et al. | Liquid biopsy-a review | |
| JP5130465B2 (ja) | 肝細胞癌マーカー及び肝細胞癌の検査方法 | |
| Hamilton | Clinical relevance of circulating tumor cells in cancer patients | |
| KR20150069092A (ko) | 뇌전이암 원인종양 진단용 조성물 및 그의 용도 | |
| Cherciu et al. | Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study |